# Product Data Sheet

Product Name: Hydroxychloroquine Impurity F
Cat. No.: GC60918

## Chemical Properties

| | | | |
|---|---|---|---|
| Cas. No. | 6281-58-9 | | |
| SMILES | CC1N(C2=CC=NC3=CC(Cl)=CC=C23)CCC1 | | |
| Formula | $C_{14}H_{15}ClN_2$ | M.Wt | 246.74 |
| Solubility | | Storage | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. | | |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request. | | |
| Structure | | | |




## Background

Hydroxychloroquine Impurity F is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].

***Caution: Product has not been fully validated for medical applications. For research use only.***
***Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com***
***Address: 10292 Central Ave. #205, Montclair, CA, USA***

# Product Data Sheet

References:
[1]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.
[2]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.
[3]. Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.

***Caution: Product has not been fully validated for medical applications. For research use only.***
***Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com***
***Address: 10292 Central Ave. #205, Montclair, CA, USA***